1 May 2022 in Moldovan Journal of Health Sciences
Background. Fatty liver disease (FLD) is composed of a wide spectrum including metabolic associated fatty liver disease (MAFLD). Cardiovascular disease (CVD) is the leading cause of mortality in this populational group. Many risk estimation systems are in existence for improving the management of population groups, but currently, none of the available risk prediction models are authenticated in patients with hepatic steatosis. Materials and methods. Transversal, observational, prospective, case control study has been included 680 patients with MAFLD and 96 control subjects without MAFLD. Experimental group was divided in tree subgroups: A - overweight or obesity (BMI ≥ 25 kg/m2 ) N= 498; B – lean/normal weight (BMI <25kg/m2 ) N= 58 and C – Type 2 diabetes mellitus N= 156. For each patient, cardiovascular risk was estimated using the Framingham equation (risk ≥ 20% – high), SCORE risk chat (risk ≥ 10% – high) and Atherosclerotic Cardiovascular Disease Risk Algorithm from the American College of Cardiology and the American Heart Association (AHA/ACC) (risk ≥ 20% – high). Results. Model Risk SCORE and Risk ACC/AHA had identified the low proportion of patients with high risk, however, Risk FRS determined the highest proportion of the patients as being ‘at high-risk’ (Risk SCORE -7% vs Risk ACC/AHA - 15% vs Risk FRS - 38%, p <0.001). Statistically significant correlations were found between the scoring systems Risk FRS and Risk ACC/AHA (Pearson’s r = 0.939, p = 0.0001, Spearman`s rho=0.960, p <0.001). The highest proportion of the patients as being ‘at high-risk’ from group C – DMT2 was found by model RiskFRS – 82.7%, with statistically significant difference between group A and B – 28.1 % vs 6.8%, p < 0.001. The same tendency was observed for RiskSCORE and Risk ACC/AHA (RiskSCORE DMT2 – 26.3% vs Risk ACC/AHA DMT2 – 46.8%), bur these scores have identified the low proportion of patients with high risk in this populational group. Conclusions. The study shows that RiskFRS appeared to be most useful CVD risk assessment model in hepatic steatosis, RiskFRS is likely to identify a greater number of patients at ‘high-risk’ as compared to Risk SCORE and Risk ACC/AHA.
1 October 2021 in The Moldovan Medical Journal
Background: It was intended to study the structure of the symptoms in patients suspected of having SARS-CoV-2 virus infection, as well as to find any correlations between the clinical, paraclinical and radiological manifestations in positive versus negative patients, in order to further facilitate the diagnosis and triage of patients. Material and methods: 101 patients seeking medical attendance at the COVID-19 Triage Center in Chisinau have been examined, presenting various respiratory symptoms. The frequency of symptoms and the results of the paraclinical investigations were evaluated based on the results of the PCR tests for SARS-CoV-2 infection and the assessment of correlations (Pearson). Results: Out of 101 subjects, 50 tested SARS-CoV-2 positive, and the remaining 51 – negative. The clinical manifestations of SARS-CoV-2 suspects were as follows: fatigue – 72%, sweating – 54%, chills – 52%, fever – 49%, subfebrility – 39%, myalgias and arthralgias – 37%, cough – 35% (sputum – 17% and hemoptysis – 2%), dyspnea – 34%, chest pain – 23%, anosmia – 12%, headache – 11%, dyspeptic syndrome – 8%. Infiltrates on chest radiography were found in 22% of cases. A weak inverse correlation (R = -0.22, P <0.05) between the leukocyte count and SARS-CoV-2 test results was found. An average direct correlation between the presence of fever (R = 0.36, P <0.05) and a positive COVID-19 test was also noticed. Conclusions: Certain symptoms such as anosmia were more commonly seen in patients with positive COVID-19 tests. The absence of pulmonary infiltrates and the presence of dyspnoea have been negative predictive factors for COVID-19. Leukopenia has been noticed only in SARS-CoV-2 positive patients. Subfebrility has not shown a predictive significance of COVID-19
7 September 2020 in European Respiratory Journal
Background: In the last few years, many investigators focused their attention on the relationship between COPD and ischemic heart disease, showing that these diseases are mutually influenced. Aim: To study the dependence of myocardial ischemia on COPD stage. Material and Methods: The study included 115 patients (mean age 56,6±5.75 years) with stable COPD divided into 3 groups, depending on the GOLD stage of the disease: groupe 1 – 39 patients with stage 1, groupe 2 – 36 patients with stage 2 and groupe 3 – 40 patients with stage 3. The patients were investigated clinically and paraclinically: spirometry, electrocardiography, echocardiography, 24-hour Holter monitoring, arterial blood gasometry. Results: The results of the study showed that MI was detected in 32 patients (27.8%). In group 1 MI was detected in 8 (20.5%) patients, in group 2 – in 8 (22.2%) patients and in group 3 – in 16 (40.0%) patients.. It should be noted that in a number of patients, ischemic changes had several localizations. Most often, ischemic changes were detected in the region of the anterior, lower and lateral wall of the left ventricle myocardium - 34.4%, 30% and 35.6% of cases, respectively. The painless form of ischemia was observed more often than the pain form: the ratio was 1.5 / 1, respectively. Conclusion: MI are quite common in COPD patients, and its incidence increases as the disease progresses.